prikaz prve stranice dokumenta Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
  Preuzmi
PDF 411.71 KB
Znanstveni rad - Izvorni znanstveni rad
Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
Endocrine, 52 (2016), 3; 602-608. https://doi.org/10.1007/s12020-015-0846-9
Prpić, Marin; Kruljac, Ivan; Kust, Davor; Kirigin, Lora S.; Jukić, Tomislav; Dabelić, Nina; Bolanča, Ante; Kusić, Zvonko

Citirajte ovaj rad

Prpić, M., Kruljac, I., Kust, D., Kirigin, L. S., Jukić, T., Dabelić, N. ... Kusić, Z. (2016). Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma. Endocrine, 52. (3), 602-608. doi: 10.1007/s12020-015-0846-9

Prpić, Marin, et al. "Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma." Endocrine, vol. 52, br. 3, 2016, str. 602-608. https://doi.org/10.1007/s12020-015-0846-9

Prpić, Marin, Ivan Kruljac, Davor Kust, Lora S. Kirigin, Tomislav Jukić, Nina Dabelić, Ante Bolanča i Zvonko Kusić. "Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma." Endocrine 52, br. 3 (2016): 602-608. https://doi.org/10.1007/s12020-015-0846-9

Prpić, M., et al. (2016) 'Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma', Endocrine, 52(3), str. 602-608. doi: 10.1007/s12020-015-0846-9

Prpić M, Kruljac I, Kust D, Kirigin LS, Jukić T, Dabelić N, i sur.. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma. Endocrine [Internet]. 2016. [pristupljeno 29.11.2024.];52(3):602-608. doi: 10.1007/s12020-015-0846-9

M. Prpić, et al., "Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma", Endocrine, vol. 52, br. 3, str. 602-608, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:946237. [Citirano: 29.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:946237
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
AutorMarin Prpić
AutorIvan Kruljac
AutorDavor Kust
AutorLora S. Kirigin
AutorTomislav Jukić
AutorNina Dabelić
AutorAnte Bolanča
AutorZvonko Kusić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
The aim of this study was to evaluate the efficacy of different radioactive iodine (I-131) activities used for re-ablation, to compare various combinations of treatment activities, and to identify predictors of re-ablation failure in low- and intermediate-risk differentiated thyroid carcinoma (DTC) patients. The study included 128 consecutive low- and intermediate-risk patients with DTC with ablation failure after total thyroidectomy. Patient characteristics, T status, tumor size, lymph node involvement, postoperative remnant size on whole-body scintigraphy, serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH), anti-Tg antibody (TgAb), and Tg/TSH ratio were analyzed as potential predictors of the re-ablation success. Re-ablation was successful in 113 out of 128 patients (88.3 %). Mean first I-131 activity was 2868 ± 914 MBq (77.5 ± 24.7 mCi) and mean second I-131 activity 3004 ± 699 MBq (81.2 ± 18.9 mCi). There was no association between the first, second, and cumulative activity with re-ablation treatment outcome. Treatment failure was associated with higher Tg levels prior to re-ablation (Tg2) (OR 1.16, 95 % CI 1.05-1.29, P = 0.003) and N1a status (OR 3.89, 95 % CI 1.13-13.41, P = 0.032). After excluding patients with positive-to-negative TgAb conversion, Tg2 level of 3.7 ng/mL predicted treatment failure with a sensitivity of 75.0 %, specificity of 80.5 %, and a negative predictive value of 97.1 %. Patients with positive-to-negative TgAb conversion had higher failure rates (OR 2.96, 95 % CI 0.94-9.29). Re-ablation success was high in all subgroups of patients and I-131 activity did not influence treatment outcome. Tg may serve as a good predictor of re-ablation failure. Patients with positive-to-negative TgAb conversion represent a specific group, in whom Tg level should not be used as a predictive marker of treatment outcome.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaEndocrine
Brojčani podacivol. 52, br. 3, str. 602-608
p-ISSN1355-008X
DOIhttps://doi.org/10.1007/s12020-015-0846-9
URN:NBNurn:nbn:hr:105:946237
Datum objave publikacije2016
URL dokumentahttps://doi.org/10.1007/s12020-015-0846-9
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:00:45